The GR Engineering Services Ltd (ASX: GNG) share price is soaring on Tuesday as the company reported its FY21 results.

The GR Engineering share price is now trading at $1.64, a 12.71% jump into the green.

Let’s uncover how GR performed this year.

GR Engineering share price lifts on record revenue and strong earnings

The company outlined a number of investment highlights in its report, including:

• Record revenue in FY21 of $392.4 million, also a 76.4% year-on-year growth schedule
• All-time record EBITDA of $37.2 million, up from $11.3 million the year prior
• Strong operational cash flows with cash at bank of $69 million – an 84% year-on-year increase
• Profit before income tax (PBIT) of $33.7 million, from a loss of $9.7 million
• Net profit after tax (NPAT) of $14.9 million, up from a loss of $4.7 million a year ago
• Final dividend of 7 cents per share, fully franked.

What happened in FY21 for GR Engineering?

The company outlined several progress points that could potentially impact the GR Engineering share price.

The most notable takeout from GR’s FY21 earnings is that it recognised record revenue of $392.4 million, which also signifies a 76% year-on-year growth.

Moreover, the company also achieved its record EBITDA this year of $37.2 million, a 292% increase.

In addition, GR reversed the loss it posted in NPAT and PBIT last year, growing both figures to around $15 million and $34 million respectively.

Moreover, the company also detailed several project completions in FY21, such as the Thunderbox past plant project and the Lake Way Potash project.

As well, the company announced a final dividend of 7 cents per share, fully franked, up from 5 cents per share in April 2021 and 4 cents per share in October 2020. Thus, shareholders will enjoy total dividends of 12 cents per share for FY21.

As such, the company recorded earnings per share (EPS) of 14.9 cents per share, well up from a loss of 4.7 cents per share in FY20.

GR Engineering consequently left the year with a net operating cash flow of $49.5 million, up from $11.2 million the year prior.

What did management say?

GR Engineering managing director Geoff Jones said:

GR Engineering achieved multiple project completions in FY21 that were on time and on budget. The safe and successful delivery of these projects reinforces GR Engineering’s reputation as a proven process engineering design and construction contractor.

Looking forward, Jones added:

Based on GR Engineering’s strong order book and balance sheet, the business is well placed to continue to deliver returns to its shareholders through FY22 and FY23.

What’s next for GR Engineering?

According to the company, GR has a “strong order book” that is concentrated in Australian projects.

Moreover, it has been “building its pipeline for both FY22 and FY23” and forecasts FY22 revenue in the range of $440 – $460 million.

In addition, GR’s order book contains five works that “will continue into FY22”, with an additional five work opportunities in the pipeline.

The GR Engineering share price has posted a year to date return of 32%, outpacing the S&P/ASX 200 Index (ASX: XJO)’s return of about 14% this year.

The post GR Engineering (ASX:GNG) share price lifts 12% on record FY21 revenue appeared first on The Motley Fool Australia.

More reading

• Energy sector leading the ASX 200 shares on Tuesday
• Oil Search (ASX:OSH) dividend reinstated following strong first-half results
• Why Ansell, Kogan, Monadelphous, & NIB shares are tumbling lower
• 4DMedical (ASX:4DX) share price lifts on 71% income increase in FY21
• The Superloop (ASX:SLC) share price slides on FY21 earnings

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/38n6MK1

The Oil Search Ltd (ASX: OSH) dividend received a much-welcomed return today, after being suspended in the prior corresponding year. This came after the energy producer announced a strong first-half result for the 2021 financial year.

Undoubtedly, investors will be glad that the company has reinstated its dividend following a challenging time in its history.

Let’s take a peek at Oil Search’s first-half scorecard and the details regarding its upcoming interim dividend.

How did Oil Search preform in the first-half of FY21?

The Oil Search share price has rallied on the back of solid operational performance and strengthened market conditions.

For the 12 months ending 30 June 2021, Oil Search achieved US$667.7 million in revenue, up 7% on H1 FY20. The sound result benefited from a price recovery in oil and liquified natural gas (LNG) predominately in Asia. Higher realised prices coupled with management’s focus on reducing costs led to a significant improvement in the company’s financial health.

Furthermore, earnings before interest, tax, depreciation and amortisation and exploration (EBITDAX) also rose to US$489 million, reflecting an 8% increase.

On the bottom line, Oil Search posted a Net Profit After Tax (NPAT) of US$139 million. A stark contrast when comparing the company’s sizable US$266.2 million loss in the first-half of FY20.

In light of the robust performance, the Oil Search board decided to bump up its interim dividend to US3.3 cents per share.

Based on the current Oil Search share price of $3.76 apiece, this gives the company a trailing dividend yield of just over 1.21%. The payout ratio is 49% of H1 FY21’s NPAT.

Oil Search dividend key dates

Oil Search released the distribution amount and payment dates of its unfranked interim dividend for the 2021 financial year. Here’s a summary of the important dates Oil Search shareholders will need to know.

Ex-dividend date

The ex-dividend date will be 31 August 2021.

The ex-dividend date is when investors must have purchased Oil Search shares. If the investor does not buy Oil Search shares before this date, the dividend will go to the seller.

Record date

The record date for the Oil Search dividend is 1 September 2021.

This is the date where the company identifies which investors are on its register. Those who are on Oil Search’s books will be eligible to receive its upcoming dividend.

Payment date

The payment date for Oil Search’s final dividend will be 21 September 2021.

The post Oil Search (ASX:OSH) dividend reinstated following strong first-half results appeared first on The Motley Fool Australia.

More reading

• Oil Search (ASX:OSH) share price rises on $139m profit for first-half
• What happened to the Oil Search (ASX:OSH) share price last earnings season?
• 5 things to watch on the ASX 200 on Thursday
• Santos (ASX:STO) share price slumps following half-year results
• This leading fund manager thinks these ASX shares might be buys

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned.

from The Motley Fool Australia https://ift.tt/3j9XpDq

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is following the lead of US markets and pushing higher. At the time of writing, the benchmark index is up 0.3% to 7,512.5 points.

Four ASX shares that have failed to follow the market higher today are listed below. Here’s why they are tumbling lower:

Ansell Limited (ASX: ANN)

The Ansell share price has sunk 10% to $36.46 after the release of its full year results. Thanks to COVID-19 tailwinds, the company reported a 57% lift in net profit to US$248 million. However, this fell short of the consensus estimate of US$256 million. Also weighing on sentiment was its outlook. Management advised that it expects demand for medical PPE to taper off as COVID-19 impacts lessen. It also warned that disruptions to its factories and suppliers could weigh on costs.

Kogan.com Ltd (ASX: KGN)

The Kogan share price is down 14% to $11.30 after the release of its full year results. For the 12 months ended 30 June, the ecommerce company reported gross sales growth of 52.7% to $1,179 million but an 86.8% decline in net profit after tax to $3.5 million. The latter was driven by inventory issues. Unfortunately, FY 2022 has started poorly, with the company reporting a small increase in gross sales and an 80% reduction in EBITDA.

Monadelphous Group Limited (ASX: MND)

The Monadelphous share price is down 13% to $10.21. In FY 2021, the engineering company reported an 18% increase in revenue to $1.95 billion and a 29% lift in net profit after tax to $47.1 million. However, its cash flow generation was poor and its outlook was soft. Management warned that revenues would be lower in FY 2022. It also advised that the shortage of skilled labour will continue to be the major challenge.

NIB Holdings Limited (ASX: NHF)

The NIB share price is down a further 5% to $6.73. This appears to have been driven by a broker note out of Citi. In response to its results yesterday, the broker has downgraded NIB’s shares to a sell rating with a reduced price target of $6.30. It was particularly disappointed with the performance of its international business.

The post Why Ansell, Kogan, Monadelphous, & NIB shares are tumbling lower appeared first on The Motley Fool Australia.

More reading

• Kogan (ASX:KGN) dividend scrapped, share price plummets
• ASX 200 midday update: Kogan crashes, Nanosonics rockets
• FY 2021 results: Monadelphous (ASX:MND) share price crashes 14% on subdued outlook
• Kogan (ASX:KGN) share price sinks 8% after FY21 results and weak start to FY22
• Ansell (ASX:ANN) share price on watch after 57% profit surge

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Kogan.com ltd. The Motley Fool Australia owns shares of and has recommended Kogan.com ltd. The Motley Fool Australia has recommended Ansell Ltd. and NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3z8AkXk

The 4DMedical Ltd (ASX: 4DX) share price is climbing today after the medical technology company reported its FY21 earnings.

The 4DMedical share price is now $1.50, a 5.63% jump from the market open.

Let’s investigate further.

4DMedical share price jumps on strong growth in cash reserves

4DMedical outlined several investment highlights in its report, including:

• Increase in cash reserves of 860% to $80.9 million, with no debt
• Total income of $5.8 million, a 71% year-on-year increase
• 52% increase in operating costs to $24.5 million
• Net loss after tax of $21.4 million, which was down 3% from the year prior
• Successful initial public offering (IPO) by raising $50 million of investor capital.

What happened in FY21 for 4DMedical?

In a positive for the 4DMedical share price, total income growth of 71% was underscored by operating revenue and “other income” of $5.6 million, as per the release.

Moreover, as a result of its IPO, 4D was able to strengthen its balance sheet and grow its cash position by more than 860% to about $81 million year on year.

Additionally, 4D made “strong progress against its commercialisation strategy”, laying the groundwork with “the establishment of clinical trials and pilots”.

As of 30 June 2021, the company had received approval for eight clinical trials, investigating a range of applications for its “FDA-cleared and TGA approved” respiratory imaging platform. The conditions under examination in these trials span from pulmonary hypertension to constrictive bronchitis.

Recall that this imaging platform, the “XVD Scanner”, is the “world’s first dedicated lung scanner”, according to 4DMedical.

In addition, the company’s subsidiary Australian Lung Health Initiative was awarded a $28.9 million contract by the Australian Government’s Medical Research Future Fund (MRFF) to develop the XVD scanner. This initially saw a jump in the 4DMedical share price.

Furthermore, the company also secured “streamlined access” to the US Department of Defence, and also Veterans’ Affairs (VA), to implement contracts on its “XV Lung Ventilation Analysis Software (XV LVAS)”.

In a further possible boost for the 4DMedical share price, the company also secured another $46 million in capital raising to support its XVD Scanner while strengthening its balance sheet.

What did management say?

4DMedical founder and CEO Andreas Fouras said:

We are extremely proud of 4DMedical’s progress in what was a foundational year. Having successfully listed on the ASX, combined with ALHI’s MRFF grant and 4DMedical’s follow-on capital raising, the company is very well funded to support the commercialisation of our technology in one of the world’s largest markets.

We have seen a significant shift in momentum in the past few months, with our pipeline of clinical trials and pilots experiencing significant growth. Additionally, 4DMedical has been highly successful in attracting top class talent during the year, doubling our headcount to 95 employees over the period, ensuring that we are well placed to achieve our commercialisation goals in FY22 and beyond.

What’s next for 4DMedical?

4D is progressing another two pilot studies in the US with the Department of Defence and VA’s healthcare networks. Both of these networks “represent a significant opportunity for the company”.

Moreover, the company “expects key milestones to be delivered in 2022” in its XV LVAS scanner, by integrating with a “broader range of hospital equipment”, such as CT scanners.

Finally, “subsequent to the year’s end”, the company signed its “first pharmaceutical-focused contract” with Novartis. Under the contract, Novartis will use XV LVAS to “assess and validate pharmaceutical therapies” in patients with chronic obstructive pulmonary disease (COPD).

4DMedical share price snapshot

The 4DMedical share price has had a choppy year to date, posting a loss of 39% since January 1. It has also fallen around 8% in the last 12 months.

This has lagged the S&P/ASX 200 index (ASX: XJO)’s return of around 14% this year to date.

The post 4DMedical (ASX:4DX) share price lifts on 71% income increase in FY21 appeared first on The Motley Fool Australia.

More reading

• 4DMedical (ASX:4DX) share price soars on contract with $305b pharma giant
• Here’s why the 4DMedical (ASX:4DX) share price is gaining today

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3kmDuQW